|The Efficacy and Safety of Telbivudine in Korean Patients with Chronic Hepatitis B|
|Young-Myoung Moon, M.D.1, Seong-Gyu Hwang, M.D.2, Boo-Sung Kim, M.D.3,
Kyu-Sung Rim, M.D.2, Mong Cho, M.D.4, Dong-Joon Kim, M.D.5, Joon-Yeol Han, M.D.6,
Young-Seok Kim, M.D.3, Ho-Soon Choi, M.D.7, Sang-Hoon Ahn, M.D.8|
|1Department of Internal Medicine, Kwandong University College of Medicine, Gangneung, Korea
2Department of Internal Medicine, Pochon CHA University College of Medicine, Seongnam, Korea
3Department of Internal Medicine, Sooncheonhyang University College of Medicine, Seoul, Korea
4Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
5Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea
6Department of Internal Medicine, Catholic University College of Medicine, Seoul, Korea
7Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
8Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea|
Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). Clinical trials have shown that telbivudine is more potent than lamivudine for suppressing virus.
A total 101 Korean patients among 1,367 patients who participated in the phase III GLOBE trial were randomized in this study. All 101 HBeAg positive or HBeAg negative patients were assigned to treatment with 600 mg of telbivudine or 100 mg of lamivudine once daily. The primary efficacy endpoint (the "therapeutic response") was defined as suppression of the serum HBV DNA to less than 5 log10 copies/mL coupled with either normalization of the serum alanine aminotransferase level or loss of HBeAg. The secondary endpoints included the histologic response, serum HBV DNA reduction, serum alanine aminotransferase normalization and HBeAg loss for the HBeAg positive patients. This analysis includes the data collected at 52 weeks of treatment.
Fifty four of 101 patients were assigned to telbivudine treatment and 47 patients were assigned to lamivudine treatment. At week 52, significantly more patients who were treated with telbivudine than those treated with lamivudine had a therapeutic response (83% vs 62%, respectively, P=0.017), their mean serum HBV DNA levels were more reduced (6.6 vs 5.6 log10 copies/mL, respectively, P=0.027), and they more often achieved PCR-undetectable levels of serum HBV DNA (74% vs 34%, P<0.0001). No virologic resistance to telbivudine was detected (0% vs 18%, respectively, P=0.001). Telbivudine was well tolerated and it had a safety profile comparable to lamivudine.
Patients treated with telbivudine achieved earlier and more profound viral suppression than those treated with lamivudine. (Korean J Hepatol 2007;13:503-512)
Hepatitis B, chronic; Telbivudine; Treatment outcome; Adverse effect; Korean